Full Title
DCC-3009 FIH Monotherapy (Escalation and Expansion)Purpose
Researchers want to find the best dose of DCC-3009 to use in people with gastrointestinal stromal tumors (GIST). The people in this study have GIST that has metastasized (spread) after treatment. In addition, their cancers have a mutation (change) in the KIT or PDGFRA gene. These mutations are common in people with GIST and can cause cancer to grow.
DCC-3009 blocks enzymes that help cancer cells to survive and grow. By blocking these enzymes, DCC-3009 may help slow or stop the growth of your cancer. It is taken orally (by mouth).
Contact
For more information or to see if you can join this study, please call Dr. Ping Chi’s office at 646-888-4166.
Protocol
25-049
Phase
Phase I (phase 1)
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06630234
ClinicalTrials.gov